Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PPOX | P50336 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988227 | 0.83 | CES1 (0.44) | CES1AGTR1DNMT1CA1CA2 | |
| SCHEMBL5989904 | 0.83 | CA1 (0.53) | CES1AGTR1CA1CA2CA4 | |
| SCHEMBL12235587 | 0.79 | AGTR1 (0.61) | CES1AGTR1CA1CA2POLB | |
| SCHEMBL29451126 | 0.79 | CES1 (1.00) | CES1AGTR1DNMT1TRPM2DAO | |
| SCHEMBL1274994 | 0.79 | CES1 (1.00) | CES1AGTR1DNMT1TRPM2DAO | |
| SCHEMBL5738059 | 0.73 | CES1 (0.65) | CES1AGTR1DNMT1CA1CA2 | |
| SCHEMBL5739112 | 0.73 | CES1 (0.50) | CES1AGTR1CA1CA2CA4 | |
| SCHEMBL11921528 | 0.72 | CES1 (0.73) | CES1AGTR1DNMT1TRPM2DAO | |
| SCHEMBL23647047 | 0.71 | CA1 (0.62) | CES1CA1CA2CA4CA7 | |
| SCHEMBL8912592 | 0.71 | CA1 (0.62) | CES1CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CES1 1061/4885AGTR1 234/4885DNMT1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.